Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia

The authors performed a MRSI study of the anterior cingulate gyrus in 19 schizophrenic patients under stable medication and 16 controls in order to corroborate previous findings of reduced NAA in the anterior cingulate region in schizophrenia. Furthermore, correlations between NAA in the anterior cingulate gyrus and age or illness duration have been determined. A decreased NAA signal was found in the anterior cingulate gyrus of patients compared to controls. Subdividing the patient group into two groups depending on medication revealed that the group of patients receiving a typical neuroleptic medication showed a lower mean NAA in comparison to the group of patients receiving atypical antipsychotic drugs. No significant group differences in the creatine and phosphocreatine signal or the signal from choline-containing compounds were found. The NAA signal significantly correlated with age, and therefore, individual NAA values were corrected for the age effect found in the control group. The age-corrected NAA signal in schizophrenia correlated significantly with the duration of illness. The detected correlations of NAA decrease with age and illness duration are consistent with recent imaging studies where progressing cortical atrophy in schizophrenia was found. Further studies will be needed to corroborate a possible favorable effect of atypical antipsychotics on the NAA signal.

[1]  H. Meltzer,et al.  Neuropsychologic Deficits in Schizophrenia , 1996, Neuropsychopharmacology.

[2]  H. Larsson,et al.  The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. , 1993, Magnetic resonance imaging.

[3]  Daniel R. Weinberger,et al.  Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground , 1995, Schizophrenia Research.

[4]  Daniel H. Mathalon,et al.  Age-related decline in MRI volumes of temporal lobe gray matter but not hippocampus , 1995, Neurobiology of Aging.

[5]  J. Stack,et al.  Abnormalities of Cerebral Structure in Schizophrenia on Magnetic Resonance Imaging: Interpretation in Relation to the Neurodevelopmental Hypothesis , 1992, Journal of the Royal Society of Medicine.

[6]  B J Soher,et al.  Automated spectral analysis II: Application of wavelet shrinkage for characterization of non‐parameterized signals , 1998, Magnetic resonance in medicine.

[7]  G B Matson,et al.  Reduced phase encoding in spectroscopic imaging , 1994, Magnetic resonance in medicine.

[8]  V. Govindaraju,et al.  Automated spectral analysis III: Application to in Vivo proton MR Spectroscopy and spectroscopic imaging , 1998, Magnetic resonance in medicine.

[9]  D. Mathalon,et al.  A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. , 1994, Archives of neurology.

[10]  H. Fibiger,et al.  Neuroleptics increase C-FOS expression in the forebrain: Contrasting effects of haloperidol and clozapine , 1992, Neuroscience.

[11]  R W Neufeld,et al.  Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. , 1997, Archives of general psychiatry.

[12]  A. Deutch,et al.  The effects of antipsychotic drugs on fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization , 1996, Neuroscience.

[13]  J. Frahm,et al.  Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. , 1993, Radiology.

[14]  R. Roth,et al.  Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. , 1997, Science.

[15]  N. Schuff,et al.  Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia , 1997, Schizophrenia Research.

[16]  B J Soher,et al.  Automated spectral analysis I: Formation of a priori information by spectral simulation , 1998, Magnetic resonance in medicine.

[17]  H. Fibiger,et al.  Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. , 1994, The Journal of pharmacology and experimental therapeutics.

[18]  L. DeLisi,et al.  A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: Preliminary findings , 1995, Biological Psychiatry.

[19]  R. DeTeresa,et al.  Neocortical cell counts in normal human adult aging , 1987, Annals of neurology.

[20]  J. Duyn,et al.  Quantitative proton MR spectroscopic imaging of the human brain , 1996, Magnetic resonance in medicine.

[21]  G Tedeschi,et al.  Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. , 1996, The American journal of psychiatry.

[22]  B. Woods.  Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. , 1998, The American journal of psychiatry.

[23]  G. Fein,et al.  Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging. , 1997, Radiology.

[24]  R. Hemmingsen,et al.  Neuroleptics in progressive structural brain abnormalities in psychiatric illness , 1998, The Lancet.

[25]  M. Buchsbaum,et al.  Functional brain imaging and aging in schizophrenia , 1997, Schizophrenia Research.

[26]  L. DeLisi,et al.  Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia , 1997, Psychiatry Research: Neuroimaging.

[27]  B. Anderton.  Changes in the ageing brain in health and disease. , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.